Cessatech continues to perform: Danish Biotech Weekly (38)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Cessatech continued strong performance after an agreement with EMA regarding CT002, Ascendis Pharma recieved positive CHMP opinion for TransCon and several companies presented additional data to previous studies.

The past week was full of exciting news with 9 of the 20 listed Danish biotech companies publishing news. 7 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year to date. Cessatech continues to perform for the second week in a row and is now the best performing stock year-to-date.

Company news the past week

Ascendis Pharma

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism (Link)

Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency (Link)


No news the past week


Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children (Link)

CS Medica

No news the past week


Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague (Link)

Evaxion Biotech

Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development (Link)


ExpreS2ion’s Board, CEO and CFO commit to full exercise of their series TO 8 warrants (Link)

Last day of trading in warrants of series TO 8 in Expres2ion Biotechnologies is today, 18 September 2023 (Link)


No news the past week


Capital Increase in Genmab as a Result of Employee Warrant Exercise (Link)


No news the past week

Initiator Pharma

No news the past week

IO Biotech

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer (Link)

Pila Pharma

No news the past week


No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon (Link)


No news the past week

Zealand Pharma

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (Link)

Y-mAbs Therapeutics

No news the past week


No news the past week



On average, the Danish biotech stocks delivered a negative share price performance last week of -1.6%. Cessatech rose 26% after reaching an agreement with EMA regarding CT002 for medical procedural sedation in children. The week prior to last week, Cessa Cessatech A/S rose 62%. Furthermore, Ascendis Pharma recieved positive CHMP opinion for TransCon for Adults with Chronic Hypoparathyroidism as well as launched Skytrofa in Germany. On the other hand, IO Biotech fell the most with a 17% decrease. The best stocks year-to-date include Curasight, Cessatech Fluoguide, and Saniona after soaring 92-166%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 0.6%. However, it is driven by the few companies delivering very positive returns.

Read more about Curasight (in Danish): Et succesfuldt kvartal for Curasight med mere i vente

Overview of share price developments the past week, year-to-date and last twelve months


Selected cases

Would you like to receive one of our newsletters? Please fill the form below. (Newsletters are in danish)

  • Investment cases – Newsletters with current investment cases from the Nordic growth exchanges and the life science sector.
  • IPOs – Updates on new and ongoing IPOs in Scandinavia and their results. (Newsletter from Nyemission.dk)
  • Nyheder – News from and about Kapital Partner, including insight into the capital markets and stock exchange listings as well as invitations to investor meetings and events.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*If you want information about our upcoming investment association with a focus on the Nordic growth exchanges, including the opportunity to invest, sign up for the newsletter. Nyheder.

Investor network:

Do you want to be part of Kapital Partner’s investor network, where you get access to investments in companies and issues, as well as invitations to investor-oriented events,
please fill out the form in here.

Del indlægget på sociale media eller på email.